Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
Posted on: Thursday, 31 July 2008, 18:00 CDT
SOUTH SAN FRANCISCO, Calif., July 31 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology, today announced that the Company will present information on platinum resistance at the Fourth Annual Moores UCSD Cancer Center Translational Oncology Symposium on Friday, August 1, in San Diego.
Neela Patel, Ph.D., director of preclinical and translational medicine for Poniard Pharmaceuticals, will present on the topic of "Molecular Mechanisms of Platinum Resistance" at 2:30 p.m. Pacific Time. Jerry McMahon, Ph.D., chairman and chief executive officer, will participate in the symposia's concluding panel discussion at 3:15 p.m. Pacific Time.
"Each year, 300,000 cancer patients in the United States are treated with a platinum-based chemotherapy, and most relapse after initial treatment," said Dr. McMahon. "Therefore, intrinsic or acquired resistance to platinums is a significant treatment issue. Picoplatin, our lead product candidate, was designed to overcome platinum resistance, and we are exploring the use of genetic markers of platinum resistance to optimize patient treatment."
About The Rebecca and John Moores UCSD Cancer Center
The Rebecca and John Moores UCSD Cancer Center seeks to bring the finest minds in treatment and research under one roof to share the latest advances in the oncology field, and to create a fertile atmosphere that promotes networking and collaboration opportunities of benefit to all participants.
Information about the Moores UCSD Cancer Center and the Translational Oncology Symposium can be found at http://cancer.ucsd.edu/symposium/index.asp.
About Poniard Pharmaceuticals
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum therapy with an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and hormone-refractory prostate cancers, as well as a clinical trial of oral picoplatin in solid tumors. Picoplatin has not been approved by any regulatory authority for use in humans. For additional information please visit http://www.poniard.com/.
(C) 2008 Poniard Pharmaceuticals, Inc. All Rights Reserved.
Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.
Poniard Pharmaceuticals
CONTACT: Brendan Doherty, Corporate Communications of PoniardPharmaceuticals, +1-650-745-4425, bdoherty@poniard.com
Web site: http://www.poniard.com/
Source: PRNewswire-FirstCall
Related Articles
- Partial Breast Irradiation Now Provided By Rocky Mountain Oncology Center
- UCSD Medical Center Adds Hillcrest Campus to Its Awarepoint Real-Time Location System Deployment
- Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer
- Poniard Pharmaceuticals Announces Final Picoplatin Data From Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
- Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
- Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
- Awarepoint Announces Real-Time Asset Tracking Expansion at UCSD Medical Center
- Threshold Starts Trial for Platinum-Resistant Cancer Patients
- Threshold Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating Glufosfamide in Patients With Platinum-Resistant Ovarian Cancer
- Two Join Easton-Based Requard Radiation Oncology Center
User Comments (0)
RSS Feeds